Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Dmitry V Shcheblyakov

Showing results (11-20 of 34) with videos related to

Pageof 4
Sort By:
Vaccines|January 21, 2023
Revaccination in Age-Risk Groups with Sputnik V Is Immunologically Effective and Depends on the Initial Neutralizing SARS-CoV-2 IgG Antibodies LevelMikhail A Godkov, Darya A Ogarkova, Vladimir A Gushchin, et al.
International Journal of Biological Macromolecules|November 22, 2024
Structural insight into recognition of Clostridioides difficile toxin A by novel neutralizing nanobodies targeting QTIN-like motifs within its receptor-binding domainNikolai N Sluchanko, Irina V Sokolova, Irina A Favorskaya, et al.
Biochemistry. Biokhimiia|September 1, 2024
Structural Basis for Evasion of New SARS-CoV-2 Variants from the Potent Virus-Neutralizing Nanobody Targeting the S-Protein Receptor-Binding DomainNikolai N Sluchanko, Dmitry V Shcheblyakov, Larisa A Varfolomeeva, et al.
International Journal of Biological Macromolecules|May 26, 2026
Structural basis of influenza A virus neutralization by broadly reactive single-domain antibody G2.3 recognizing glycosylated epitope within hemagglutinin stem domainIgor O Ilyasov, Daria V Voronina, Timur N Baymukhametov, et al.
Frontiers in Immunology|November 6, 2023
Real-world clinical effectiveness of Tixagevimab/Cilgavimab and Regdanvimab monoclonal antibodies for COVID-19 treatment in Omicron variant-dominant periodDaria S Fomina, Marina S Lebedkina, Anna A Iliukhina, et al.
Frontiers in Immunology|April 17, 2023
rAAV expressing recombinant antibody for emergency prevention and long-term prophylaxis of COVID-19Ilias B Esmagambetov, Ekaterina I Ryabova, Artem A Derkaev, et al.
Frontiers in Immunology|May 11, 2026
Circular mRNA against CleanCap linear mRNA vectors: comprehensive comparison, expression, active and passive immunizationVladimir M Vakhtinskii, Irina L Tutykhina, Alina S Dzharullaeva, et al.
Vaccines|May 28, 2022
Retention of Neutralizing Response against SARS-CoV-2 Omicron Variant in Sputnik V-Vaccinated IndividualsDaniele Lapa, Daria M Grousova, Giulia Matusali, et al.
Frontiers in Immunology|April 8, 2026
Broadly neutralizing single-domain antibody targeting the spike NTD displays therapeutic efficacy against diverse SARS-CoV-2 variantsAnastasia I Korobkova, Irina A Favorskaya, Inna V Shuliakova, et al.
Frontiers in Immunology|June 22, 2026
Long-term protective potency of AAV vector-based SARS-CoV-2 prophylaxis in mice and non-human primatesEkaterina I Ryabova, Artem A Derkaev, Ilias B Esmagambetov, et al.
Pageof 4

Showing results (11-20 of 34) with videos related to

Sort By:
Pageof 4
Vaccines|January 21, 2023
Revaccination in Age-Risk Groups with Sputnik V Is Immunologically Effective and Depends on the Initial Neutralizing SARS-CoV-2 IgG Antibodies LevelMikhail A Godkov, Darya A Ogarkova, Vladimir A Gushchin, et al.
International Journal of Biological Macromolecules|November 22, 2024
Structural insight into recognition of Clostridioides difficile toxin A by novel neutralizing nanobodies targeting QTIN-like motifs within its receptor-binding domainNikolai N Sluchanko, Irina V Sokolova, Irina A Favorskaya, et al.
Biochemistry. Biokhimiia|September 1, 2024
Structural Basis for Evasion of New SARS-CoV-2 Variants from the Potent Virus-Neutralizing Nanobody Targeting the S-Protein Receptor-Binding DomainNikolai N Sluchanko, Dmitry V Shcheblyakov, Larisa A Varfolomeeva, et al.
International Journal of Biological Macromolecules|May 26, 2026
Structural basis of influenza A virus neutralization by broadly reactive single-domain antibody G2.3 recognizing glycosylated epitope within hemagglutinin stem domainIgor O Ilyasov, Daria V Voronina, Timur N Baymukhametov, et al.
Frontiers in Immunology|November 6, 2023
Real-world clinical effectiveness of Tixagevimab/Cilgavimab and Regdanvimab monoclonal antibodies for COVID-19 treatment in Omicron variant-dominant periodDaria S Fomina, Marina S Lebedkina, Anna A Iliukhina, et al.
Frontiers in Immunology|April 17, 2023
rAAV expressing recombinant antibody for emergency prevention and long-term prophylaxis of COVID-19Ilias B Esmagambetov, Ekaterina I Ryabova, Artem A Derkaev, et al.
Frontiers in Immunology|May 11, 2026
Circular mRNA against CleanCap linear mRNA vectors: comprehensive comparison, expression, active and passive immunizationVladimir M Vakhtinskii, Irina L Tutykhina, Alina S Dzharullaeva, et al.
Vaccines|May 28, 2022
Retention of Neutralizing Response against SARS-CoV-2 Omicron Variant in Sputnik V-Vaccinated IndividualsDaniele Lapa, Daria M Grousova, Giulia Matusali, et al.
Frontiers in Immunology|April 8, 2026
Broadly neutralizing single-domain antibody targeting the spike NTD displays therapeutic efficacy against diverse SARS-CoV-2 variantsAnastasia I Korobkova, Irina A Favorskaya, Inna V Shuliakova, et al.
Frontiers in Immunology|June 22, 2026
Long-term protective potency of AAV vector-based SARS-CoV-2 prophylaxis in mice and non-human primatesEkaterina I Ryabova, Artem A Derkaev, Ilias B Esmagambetov, et al.
Pageof 4